Etanercept·Î Ä¡·á ÁßÀÎ °­Á÷¼ºÃ´Ãß¿° ȯÀÚ¿¡¼­ ¹ß»ýÇÑ Æó Å©¸³ÅäÄÚÄí½ºÁõ 1¿¹
Pulmonary Cryptococcosis in a Patient with Ankylosing Spondylitis treated with Etanercept

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸÁö 2014³â 21±Ç 4È£ p.214 ~ p.218


ÀÓäȣ(Lim Chae-Ho) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
ÀÌ»óÇå(Lee Sang-Heon) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ·ù¸¶Æ¼½º³»°úÇб³½Ç
±èÈ£¿¬(Kim Ho-Youn) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ·ù¸¶Æ¼½º³»°úÇб³½Ç
±è¿Ï¼·(Kim Wan-Seop) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø º´¸®Çб³½Ç
°­¼ºÈñ(Kang Seong-Hui) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±Ç¼¼¿õ(Kwon Se-Woong) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±èÁö¿Ï(Kim Ji-Wan) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¹Ú¼ö¿¬(Park Soo-Youn) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¾È»óÈñ(An Sang-Hee) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
À¯Çü¹Î(Yu Hyung-Min) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±èÇØ¸²(Kim Hae-Rim) - °Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ·ù¸¶Æ¼½º³»°úÇб³½Ç

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory dis-order, commonly characterized by inflammation of axial skeleton and development of enthesopathies. Tumor ne-crosis factor inhibitors (TNFi) shows good therapeutic re-sponses in AS patients without good response to non-ster-oidal anti-inflammatory drugs. Although TNFi are rela-tively safe for AS patients, serious opportunistic infections, including tuberculosis and fungal infection, could develop. Here, according to our knowledge, we report a first Korean case of pulmonary cryptococcosis in a patient with AS treated with etanercept. A 64 year-old man with AS visited due to a newly appeared pulmonary nodule on a routine chest radiography. He had been administered eta-nercept for 5 months. Histologic findings of the lung nod-ule showed characteristic features of cryptococcosis. Etanercept was discontinued and oral fluconazole was ad-ministrated, as there was no evidence of central nervous system involvement. After 7 months of treatment, chest CT showed an improvement of the pulmonary lesion.

Ű¿öµå

Ankylosing spondylitis, Pulmonary crypto-coccosis, Etanercept, Tumor necrosis factor inhibitor
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå